Search Results

Elysium Therapeutics today announced positive results from a Phase 1, human-proof-of-concept study (O2P-001) investigating the company’s proprietary Oral Overdose Protected (O2P™) hydrocodone prodrug for the treatment of moderate-to-severe acute pain.

Elysium Health, Inc.™, a leading life sciences company focused on aging research, today announced that the detailed results from its clinical trial on Basis™ (NRPT) in people with non-alcoholic fatty liver disease (NAFLD) were published in Hepatology.

Elysium Health, Inc.™, a leading life sciences company focused on aging research, has entered into a material transfer agreement with the University of Oxford to examine hundreds of samples from the VITACOG study to develop epigenetic measures of brain aging and health.

Elysium Health, Inc. has entered into a material transfer agreement with the University of Oxford to analyze the DNA methylation patterns of 2,500 umbilical cord blood samples from the landmark INTERBIO-21st Study.

Elysium Health, Inc.™, a leading life sciences company focused on aging research, today announced the initiation of research at Mayo Clinic to study associations between circulating nicotinamide adenine dinucleotide (NAD+) levels in healthy adults and senescent cell burden, and to develop novel epigenetic measures of cellular senescence.

Vistagen announced today that for the second consecutive year it has been recognized by Mental Health America (MHA) for its dedication to promoting mental health and well-being in the workplace.

Sinaptica Therapeutics, Inc. today announced that it has been selected to join StartUp Health’s Alzheimer’s Moonshot.

Observational studies to focus on patients with addiction and end-of-life distress pending formal approval and permitting from Thai health authorities